Treatment of Refractory Dry Eye Associated with Graft Versus Host Disease with 0.03% Tacrolimus Eyedrops
| Autor: | Manuel Díaz-Llopis, Patricia Udaondo, Salvador Garcia-Delpech, Amparo Vazquez, Empar Sanz-Marco |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Punctal plug medicine.medical_specialty Visual acuity medicine.medical_treatment Graft vs Host Disease Dry Eye Syndromes Administration Ophthalmic Pilot Projects Drug Administration Schedule Tacrolimus Refractory medicine Humans Pharmacology (medical) Prospective Studies Prospective cohort study Bone Marrow Transplantation Pharmacology business.industry Original Articles Middle Aged medicine.disease eye diseases Surgery Ophthalmology Artificial tears Treatment Outcome Graft-versus-host disease Female Ophthalmic Solutions medicine.symptom business Immunosuppressive Agents |
| Zdroj: | Journal of Ocular Pharmacology and Therapeutics. 29:776-783 |
| ISSN: | 1557-7732 1080-7683 |
| DOI: | 10.1089/jop.2012.0265 |
| Popis: | We investigate the efficacy of 0.03% topical tacrolimus eyedrops for the treatment of dry eye in graft versus host disease (GVHD) patients resistant/intolerant to 0.05% topical cyclosporine.Forty-three patients were enrolled in this prospective study. After completing a 1-year run-in period of using artificial tears, 50% autologous serum eyedrops, and punctal plug occlusion, all the symptomatic patients (n=29) were treated with 0.05% topical cyclosporine (Restasis(®); Allergan, Inc.). After 1 month, the patients who presented topical or systemic intolerance to cyclosporine were instructed to instill 0.03% topical tacrolimus once a day for 3 months (n=14). All the patients were allowed to continue with their basal dry eye treatment. Visual acuity, fluorescein staining, Schirmer test, fluorescein tear break-up time, and tear meniscus height measurement were evaluated fortnightly (minimum 3 months). Subjective assessments of symptoms were also reported at the beginning and at the end of the study.Dry eye symptoms and signs improved statistically (P0.05) and significantly with tacrolimus and cyclosporine topical treatment. No significant differences were observed between both the groups. The mean follow-up time was 12.14±2.69 months (range 10-18 months).The findings of this prospective pilot study suggest that cyclosporine-intolerant patients with dry eye associated with GVHD can be effectively treated with topical tacrolimus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|